A PHASE III MULTI-CENTER, OPEN-LABEL, SPONSOR-BLINDED, RANDOMIZED STUDY OF AZD0901 MONOTHERAPY COMPARED WITH INVESTIGATOR¿S CHOICE OF THERAPY IN SECOND- OR LATER-LINE ADULT PARTICIPANTS WITH ADVANCED/METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA EXPRESSING CLAUDIN18.2

Registry ID

D9802C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2025-09-04

Last update

2023-12-20

Conditions

• ADENOCARCINOMA

Related clinical trials

• PHASE II TRIAL OF PERIOPERATIVE PD-L1 INHIBITION WITH AVELUMAB AND DOCETAXEL, CISPLATIN, AND 5-FLUOROURACIL FOR RESECTABLE LOCALLY ADVANCED ESOPHAGO-GASTRIC ADENOCARINOMA
• "A PHASE III, RANDOMIZED, OPEN-LABEL CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) VERUS PACLITAXEL IN SUBJECTS WITH ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA WHO PROGRESSED AFTER FIRST-LINE THERAPY WITH PLATINUM AND FLUOROPYRIMIDINE."

View on source registry